ea0056gp208 | Pituitary Clinical | ECE2018
Vilar Lucio
, Vilar Clarice
, Lyra Ruy
, The Ana Carolina
, Trovao Erik
, Gadelha Patricia
, Cardozo Izabela
, Borges Thaize
, Sampaio Icaro
, Ferreira Liana
, Albuquerque Luciano
Background: Dopamine agonists (DA) are the treatment of choice of prolactinomas. Cabergoline is preferable to bromocriptine due to its greater effectiveness and better tolerabilitiy. However, up to 3050% of male patients may persist with low levels of testosterone despite prolactin (PRL) normalization under DA therapy or the use of the maximum tolerated dose of DA. The aim of this prospective open study was to evaluate the efficacy of the SERM clomiphene citrate (CC) in ...